Ventana Clinical Research Announces Capacity Expansion of Early-Phase Study Facility

Share Article

Ventana Clinical Research Corporation today announced an expansion of its Toronto early-phase study facility. The state-of-the-art modular clinic, specializing in Phase 1 and central nervous system (CNS) drug development, can now accommodate 128 outpatient subjects and 80 overnight patients.

Past News Releases

RSS

Ventana Clinical Research Corporation (http://www.ventana-crc.com) today announced an expansion of its Toronto early-phase study facility. The state-of-the-art modular clinic, specializing in Phase 1 and central nervous system (CNS) drug development, can now accommodate 128 outpatient subjects and 80 overnight patients.

According to Dr. Suzanne Peeters, Chief Operating Officer for Ventana, "We are responding to an increased market demand for early-phase clinical trial research capacity, particularly for CNS development".

Founded in 1997, Ventana is a leading provider of early stage specialty studies to pharmaceutical and biotechnology companies. Ventana has significant experience with clinical trial management as well as measuring the drug effect of CNS products and utilizes validated, proprietary software to enable real time capture of pharmacodynamic data.

For more information about Ventana Clinical Research visit http://www.ventana-crc.com or contact us at sales (at) ventana-crc.com

###

Share article on social media or email:

View article via:

Pdf Print